Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?

• Published in: Breast cancer research : BCR Vol. 6; no. 1; pp. R38 - R45
• Main Authors: Granato, Anna Maria, Nanni, Oriana, Falcini, Fabio, Folli, Secondo, Mosconi, Gabriella, De Paola, Franca, Medri, Laura, Amadori, Dino, Volpi, Annalisa
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.11.2003; National Library of Medicine - MEDLINE Abstracts; BioMed Central
• Subjects: Aged; Aged, 80 and over; Biomarkers, Tumor - biosynthesis; Biomarkers, Tumor - blood; Breast cancer; Breast Neoplasms - blood; Breast Neoplasms - diagnosis; Breast Neoplasms - metabolism; Cancer patients; Care and treatment; Case-Control Studies; Enzymes; Female; Fibroblast Growth Factor 2 - biosynthesis; Fibroblast Growth Factor 2 - blood; Fibroblast growth factors; Health aspects; Humans; Immunoenzyme Techniques - methods; Immunohistochemistry; Medical research; Medicine, Experimental; Middle Aged; Sensitivity and Specificity; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - biosynthesis; Vascular Endothelial Growth Factor A - blood; Women
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/bcr745

The aim of the present study was to analyze the relationship between the expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in breast cancer cells and the corresponding serum levels in individual patients. The study also evaluated the potential of serum levels of the two growth factors as diagnostic markers in a case-control study. VEGF expression and bFGF expression were determined in 62 and 63 tumor samples, respectively. Serum VEGF and bFGF levels were determined in 54 and 65 healthy women and in 69 and 73 breast cancer patients, respectively, using a quantitative sandwich enzyme immunoassay technique. A direct correlation was observed between VEGF expression and bFGF expression in individual tumors (P = 0.001) and between serum levels (P = 0.038) in individual patients, but not between tumor cell expression and the corresponding serum level for either growth factor. Median values of serum levels in healthy women and breast cancer patients were not different for VEGF (P = 0.055), but were significantly different for bFGF (P < 0.001). The receiver operating characteristic curve identified a serum bFGF concentration of 1.0 pg/ml, with 84.9% sensitivity and 63.1% specificity, as the best cut-off value to discriminate between healthy women and breast cancer patients. An age-based subgroup analysis showed that serum values of patients older than 70 years of age mainly contributed to the high accuracy. Our data repropose bFGF as a noninvasive diagnostic tool for breast cancer.